Skip Navigation


Carcinogenesis Advance Access originally published online on April 8, 2004
Carcinogenesis 2004 25(9):1575-1585; doi:10.1093/carcin/bgh159
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/9/1575    most recent
bgh159v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Guweidhi, A.
Right arrow Articles by Friess, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guweidhi, A.
Right arrow Articles by Friess, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.25 no.9 © Oxford University Press 2004; all rights reserved.

ARTICLE

Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis

Ahmed Guweidhi1, Jörg Kleeff1, Nathalia Giese1, Jamael El Fitori1, Knut Ketterer1,3, Thomas Giese2, Markus W. Büchler1, Murray Korc3 and Helmut Friess1,4

1 Department of General Surgery, University of Heidelberg, Germany, 2 Department of Immunology, University of Heidelberg, Germany and 3 Departments of Medicine, and Pharmacology and Toxicology, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH 03756, USA

4 To whom correspondence should be addressed Email: helmut_friess{at}med.uni-heidelberg.de

14-3-3sigma belongs to the 14-3-3 family of proteins, which are involved in the modulation of diverse signal transduction pathways. Loss of 14-3-3sigma expression has been observed in a number of human cancers, suggesting that it may have a role as a tumor suppressor gene. The aim of the study was to investigate the expression and the functional role of 14-3-3sigma in pancreatic ductal adenocarcinoma (PDAC). Expression of 14-3-3sigma was analyzed using laser capture microdissection (LCM), quantitative real-time–PCR (QRT–PCR), DNA arrays, immunohistochemistry and western blot analysis. The role of 14-3-3sigma in apoptosis and cell cycle regulation was evaluated by western blotting, immunoprecipitation and FACS analysis. By QRT–PCR, 14-3-3sigma mRNA levels were 54-fold increased in pancreatic adenocarcinoma in comparison with normal pancreatic samples and localized in pancreatic cancer cells as determined by LCM. In pancreatic cancer cells, the degree of 14-3-3sigma expression was not decisive for the maintenance of G2/M cell cycle checkpoint or induction of apoptosis. Responses to radiation or apoptosis-inducing agents were neither accompanied by a significant 14-3-3sigma accumulation nor by a change in association of 14-3-3sigma with cdc2, bad and bax. In conclusion, the marked over-expression of 14-3-3sigma in PADC together with multiple known genetic and epigenetic alterations of potential 14-3-3sigma interacting partners suggests an important role of aberrant 14-3-3sigma downstream signaling in pancreatic cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
G. Saturno, M. Pesenti, C. Cavazzoli, A. Rossi, A. M. Giusti, B. Gierke, M. Pawlak, and M. Venturi
Expression of Serine/Threonine Protein-Kinases and Related Factors in Normal Monkey and Human Retinas: The Mechanistic Understanding of a CDK2 Inhibitor Induced Retinal Toxicity
Toxicol Pathol, December 1, 2007; 35(7): 972 - 983.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. C. Cunningham, F. Kamangar, M. P. Kim, S. Hammoud, R. Haque, C. A. Iacobuzio-Donahue, A. Maitra, R. Ashfaq, S. Hustinx, R. E. Heitmiller, et al.
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 281 - 287.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.